Open AccessRapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
Author(s) -
Jason Bacharach,
David Wirta,
Robert Smyth-Medina,
Michael S Korenfeld,
Shane Kannarr,
Shane Foster,
Mark Jaros,
Charles B. Slonim
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s306155
Subject(s) - oxymetazoline , medicine , eyelid , anesthesia , placebo , ophthalmology , adrenergic receptor , receptor , alternative medicine , pathology
Oxymetazoline 0.1% is a novel ophthalmic agent for the treatment of acquired blepharoptosis in adults that has been shown to improve upper eyelid elevation and superior visual field deficits. This analysis characterized the rapid onset of upper eyelid elevation with once-daily oxymetazoline 0.1% and durability of this effect over 42 days.